5435-91-6

Usage

Uses

Used in Fragrance Industry:
5,5-DIMETHYL-3-OXO-HEXANOIC ACID ETHYL ESTER is used as a fragrance ingredient for its ability to impart a sweet, fruity note to perfumes and scented products, enhancing the sensory experience of various cosmetics and personal care items.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, 5,5-DIMETHYL-3-OXO-HEXANOIC ACID ETHYL ESTER is utilized for its unique chemical properties, which may contribute to the development of new drugs or medicinal compounds.
Used in Agrochemical Industry:
Similarly, the compound finds potential applications in the agrochemical industry, where its distinctive chemical attributes could be leveraged for the creation of novel agrochemical products.
Safety Note:
It is crucial to handle 5,5-DIMETHYL-3-OXO-HEXANOIC ACID ETHYL ESTER with care and adhere to safety protocols during its use, as improper handling may result in hazards.

InChI:InChI=1/C10H18O3/c1-5-13-9(12)6-8(11)7-10(2,3)4/h5-7H2,1-4H3

Upstream product

• 590-50-1 4,4-dimethyl-pentan-2-one 
• 105-58-8 Diethyl carbonate 
• 1070-83-3 tert-Butylacetic acid 
• 7065-46-5 3,3-dimethylbutanoic acid chloride 
• 623-73-4 diazoacetic acid ethyl ester 
• 2987-16-8 3,3-dimethylbutyrylaldehyde 
• 141-78-6 ethyl acetate 
• 1071-46-1 hydrogen ethyl malonate 

Downstream Products

• 81408-09-5 5,5-Dimethyl-3-oxo-2-(3-oxo-cyclohexyl)-hexanoic acid ethyl ester 
• 1414356-81-2 C₂₆H₄₀N₄O₂ 
• 81408-14-2 3-(4,4-Dimethyl-2-oxo-pentyl)-cyclohexanone 
• 153626-00-7 (2-Neopentyl-3-furyl)(tert-butyl)methyl benzoate 
• 153625-95-7 2-Neopentyl-3-furylmethyl benzoate 
• 158362-77-7 (3S,2'R)-ethyl 3-(2-methoxy-2-phenylacetamido)-5,5-dimethylhexanoate 
• 158362-76-6 (3R,2'R)-ethyl 3-(2-methoxy-2-phenylacetamido)-5,5-dimethylhexanoate 
• 87031-30-9 5-tert. Butyl-3,4-dihydro-2-methyl-2H-pyrazol-3-on 
• 6631-89-6 5-(tert-butyl)-2-phenyl-2,4-dihydro-3H-pyrazol-3-one 
• 1361979-12-5 ethyl 5,5-dimethyl-3-oxo-2,2-bis(4-phenyl-1H-1,2,3-triazol-1-yl)hexanoate 

Relevant academic research and scientific papers

Screening, synthesis, crystal structure, and molecular basis of 6-amino-4-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitriles as novel AKR1C3 inhibitors

AKR1C3 is a promising therapeutic target for castration-resistant prostate cancer. Herein, an evaluation of in-house library discovered substituted pyranopyrazole as a novel scaffold for AKR1C3 inhibitors. Preliminary SAR exploration identified its derivative 19d as the most promising compound with an IC50 of 0.160 μM among the 23 synthesized molecules. Crystal structure studies revealed that the binding mode of the pyranopyrazole scaffold is different from the current inhibitors. Hydroxyl, methoxy and nitro group at the C4-phenyl substituent together anchor the inhibitor to the oxyanion site, while the core of the scaffold dramatically enlarges but partially occupies the SP pockets with abundant hydrogen bond interactions. Strikingly, the inhibitor undergoes a conformational change to fit AKR1C3 and its homologous protein AKR1C1. Our results suggested that conformational changes of the receptor and the inhibitor should both be considered during the rational design of selective AKR1C3 inhibitors. Detailed binding features obtained from molecular dynamics simulations helped to finally elucidate the molecular basis of 6-amino-4-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitriles as AKR1C3 inhibitors, which would facilitate the future rational inhibitor design and structural optimization.

Design and synthesis of potent hydroxyethylamine (HEA) BACE-1 inhibitors carrying prime side 4,5,6,7-tetrahydrobenzazole and 4,5,6,7- tetrahydropyridinoazole templates

A set of low molecular weight compounds containing a hydroxyethylamine (HEA) core structure with different prime side alkyl substituted 4,5,6,7-tetrahydrobenzazoles and one 4,5,6,7-tetrahydropyridinoazole was synthesized. Striking differences were observed on potencies in the BACE-1 enzymatic and cellular assays depending on the nature of the heteroatoms in the bicyclic ring, from the low active compound 4 to inhibitor 6, displaying BACE-1 IC50 values of 44 nM (enzyme assay) and 65 nM (cell-based assay).

Highly twisted C=C double bonds in 4-methyleneisoxazolones

As determined by X-ray crystallography, isoxazol-5(4H)-one derivatives 1219 feature dihedral angles around the exocyclic C4=C6 double bonds of 2690. In the most highly twisted bis-tert-butylamino derivatives 18 and 19, the C4C6 bonds are essentially single bonds. Density functional theory calculations at the B3LYP/6-31G(d) level with inclusion of a simulated solvent field, which helps stabilize zwitterionic structures, are in good agreement with the experimental crystallographic data. A good correlation between bond lengths and calculated π/π*orbital occupation quotients is observed. A good correlation between the twisting angle and the charge separation, measured by the calculated negative charge on the isoxazolone moiety, is also observed. Low barriers to rotation about the twisted exocyclic double bonds C4=C6 in compounds 13, 20, and 21 (G ? = 1516 kcal mol-1 (6367 kJ mol -1)) were determined by dynamic 1H NMR coalescence measurements. The rotational barrier for 17 was estimated to be less than 10 kcal mol-1. The rotational barriers for compounds 10 and 18 were calculated to be ～8 kcal mol-1. CSIRO 2009.

Acylaminothiazole derivatives, preparation and therapeutic use thereof

This invention discloses and claims a compound conforming to the general formula (I): Wherein R1, R2, R′2, R3, R4 and R5 are as described herein. The compounds of the present invention exhibit an inhibitory effect on the production of β-amyloid peptide (β-A4) by inhibition of gamma protease. Therefore, the compounds of the present invention are useful in the treatment of pathologies such as senile dementia, Alzheimer's disease, Down's syndrome, Parkinson's disease, amyloid angiopathy and/or cerebrovascular disorders.

PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

Effects of α-tert-Butyl Group Substitution on the Reactivity and Dimerization Products of Furan-Based o-Quinodimethanes

Flash vacuum pyrolysis (FVP) of 2-neopentyl-3-furylmethyl benzoate (8) produces 3-methylene-2-(tert-butylmethylene)-2,3-dihydrofuran (5), the major product as shown by low-temperature 1H NMR spectroscopy.Upon warming to room temperature, 5 dimerizes giving mostly two stereoisomeric dimers 11a and 11b in addition to a small amount of the dimer 12.FVP of a mixture of the two dimers 11a and 11b gives the thermodynamically more stable dimer 12.The rate constants for the dimerization of 5 in solution at temperatures from -29 to +5 deg C were determined by 1H NMR spectroscopy.The rate constants and activation parameters (ΔH(excit.) = 10.8 kcal/mol, ΔS(excit.) = -28.8 eu) are very similar to those reported for the unsubstituted furan-based o-quinodimethane.FVP of (2-methyl-3-furyl)(tert-butyl)methyl benzoate (13) and (2-neopentyl-3-furyl)(tert-butyl)methyl benzoate (18) give as the major product, 2-methylene-3-(tert-butylmethylene)-2,3-dihydrofuran (6) and 2,3-bis(tert-butylmethylene)-2,3-dihydrofuran (7), respectively.Compunds 6 and 7, in contrast to 5, are stable at room temperature apparently because for each of these compounds a bulky tert-butyl group is on the more reactive methylene, the 3-methylene.These results offer further support for the mechanism for the dimerization of furan-based o-quinodimethanes which proceeds in two steps via a transient diradical intemediate.

Enones with Strained Double Bonds. 7. Precursors for Substituted Bicyclononane Systems

Compounds 11c, 12, and 13 have been synthesized as potential precursors for the 2-substituted bicyclonon-1(2)-en-3-ones 5 (R = Ph and t-Bu).The lactone 34 and its derivatives 32 have also been synthesized as potential precursors for the parent bicyclo enone 1.